Pricing Log in Create free account

Bio-Rad Laboratories, Inc. (BIO.B) vs 10x Genomics (TXG)

Bio-Rad Laboratories, Inc. and 10x Genomics are both Medical Devices companies. Bio-Rad Laboratories, Inc. is the larger, with a market value of $10.3B against $7.6B — 1.4× the size. 10x Genomics has negative trailing earnings, so its P/E is not meaningful; Bio-Rad Laboratories, Inc. trades at 9.9×. Bio-Rad Laboratories, Inc. grew revenue faster over the last twelve months: 1.38% against −4.28%. Bio-Rad Laboratories, Inc. has the higher net margin (39.5% vs −12.2%) and the higher return on invested capital (−0.44% vs −20.2%). Across the 20 metrics below, Bio-Rad Laboratories, Inc. leads on 14 and 10x Genomics on 6.

Valuation

Metric BIO.B TXG Medical Devices median
P/E 9.95 n/m 25.58
P/S 3.92 12.35 2.54
P/B 1.34 9.23 2.48
Price to free cash flow 30.74 63.28 28.81
EV/EBITDA n/m n/m 11.51
EV/Sales 3.76 11.51 2.72
Earnings yield 10.06% (1.01%) (12.82%)
Free cash flow yield 3.25% 1.58% (8.18%)

Profitability

Metric BIO.B TXG Medical Devices median
Gross margin 51.26% 70.03% 57.76%
Operating margin (2.39%) (14.33%) (15.07%)
Net margin 39.45% (12.18%) (14.45%)
Free cash flow margin 18.05% 19.68% (3.88%)
Return on equity 14.27% (9.40%) (10.35%)
Return on assets 9.99% (7.47%) (17.26%)
Return on invested capital (0.44%) (20.20%) (5.27%)

Growth

Metric BIO.B TXG Medical Devices median
Revenue growth (TTM) 1.38% (4.28%) 10.41%
EPS growth (last fiscal year) 142.61% 76.97% 28.17%
Revenue growth, 5-year CAGR 0.29% 16.55% 15.74%
Net income growth, 5-year CAGR (27.58%) 0.00% 0.00%

Health

Metric BIO.B TXG Medical Devices median
Debt to equity 0.16 0.00 0.04
Current ratio 3.18 5.69 2.74
Net debt to EBITDA (7.15) 30.49 0.54

Dividend

Metric BIO.B TXG Medical Devices median
Dividend yield — — 1.02%
Payout ratio — — 0.37

Size

Metric BIO.B TXG Medical Devices median
Market cap 10.33b 7.56b 239.53m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack